Nyxoah SA (NYXH) Reports Q3 Loss, Tops Revenue Estimates

Core Insights - Nyxoah SA reported a quarterly loss of $0.68 per share, which was worse than the Zacks Consensus Estimate of a loss of$0.46, marking an earnings surprise of -47.83% [1] - The company generated revenues of $1.73 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 17.72$1.06 million year-over-year [2] - Nyxoah shares have appreciated approximately 114.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 21.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.45 on revenues of$2.74 million, while for the current fiscal year, the estimate is -$1.86 on revenues of$6.39 million [7] - The estimate revisions trend for Nyxoah is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical Info Systems industry, to which Nyxoah belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Definitive Healthcare Corp., is expected to report results soon, with a consensus EPS estimate of $0.08 per share, reflecting a year-over-year decline of 11.1% [9]